Cite
APA Citation
Acosta, R. K., Willkom, M., Andreatta, K., Liu, H., Martin, R., Parvangada, A., Martin, H., Collins, S., & White, K. L. (2020). switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. Journal of acquired immune deficiency syndromes, 85, . http://access.bl.uk/ark:/81055/vdc_100152022835.0x000016